Dyadic International (NASDAQ:DYAI) Major Shareholder Sells $79,200.00 in Stock

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 40,000 shares of Dyadic International stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $1.98, for a total value of $79,200.00. Following the transaction, the insider owned 3,410,664 shares of the company’s stock, valued at $6,753,114.72. This represents a 1.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Dyadic International Stock Down 6.0%

DYAI opened at $1.00 on Thursday. Dyadic International Inc. has a 1-year low of $0.65 and a 1-year high of $1.35. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $0.83. The company has a current ratio of 2.42, a quick ratio of 2.42 and a debt-to-equity ratio of 4.08. The stock has a market cap of $36.33 million, a PE ratio of -4.33 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The company had revenue of $1.11 million during the quarter, compared to analyst estimates of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%. As a group, research analysts expect that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Institutional Trading of Dyadic International

A number of large investors have recently bought and sold shares of the business. Apis Capital Advisors LLC acquired a new stake in Dyadic International during the third quarter worth approximately $1,817,000. Landscape Capital Management L.L.C. acquired a new position in Dyadic International in the third quarter valued at approximately $190,000. Marathon Capital Management grew its position in shares of Dyadic International by 142.9% during the 4th quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock worth $80,000 after buying an additional 50,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the period. Finally, Bank of America Corp DE lifted its position in shares of Dyadic International by 16,146.7% during the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. 27.95% of the stock is currently owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.